Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

Podcast

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, both of the Lymphoma Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, spoke with CancerNetwork® about their review published in the journal ONCOLOGY® titled Current Treatment of Peripheral T-cell Lymphoma.

In the article, Stuver and Epstein-Peterson explored current approaches to the diagnosis and treatment of peripheral T-cell lymphoma and novel emerging strategies clinicians who are practicing in the community should be aware of.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Related Content